Your Medicines.
Our Responsibility.

We provide quality and affordable biological medicines to more patients across Africa and the Middle East

Healthcare in Africa

Carrying a Disproportionate Share of Global Disease Burden

While 16 % of the world population live in Africa, the continent carries a disproportionate 23 % share of the global disease burden, during only 1 % of the global health expenditure and 2 % of the global doctors.


60 % of the population in Africa live in rural isolated areas, and 83 % are excluded from healthcare services


Low, resulting in poor outcome; As many as 80 % of cancer patients are diagnosed in late/ end stage


High cost combined with out of pocket payments limit access to biologic treatments


0.3 physicians, 1.0 nurses, 1.3 hospital beds per 1,000 people


Bringing Critical Medicines and Services to Patients

To serve the needs of patients across Africa and the Middle East (MEA region) MiGenTra created a holistic approach around our three modalities to cover all key drivers towards a better Healthcare in Africa – our TREAT strategy.





Biologics Developed and Manufactured
In-House to Ensure Affordable Access

MiGenTra combines the extensive scientific and manufacturing expertise from both parent companies, ProBioGen and Minapharm Pharmaceuticals, for product development and commercialization in the field of three modalities.


Cell and Gene Therapies (CGT)



Be Part of the Transformation of Healthcare

Please calculate 4 plus 7.

If you provided a telephone number or an email address above, you hereby consent into us (see legal notice) contacting you using one of the given communication channels in order to reply to your request.

Note: The right to object concerns the processing of data based on our legitimate interest (Art. 6 lit. f GDPR) as well as the processing for direct marketing. You can revoke your consent at any time for the future by e-mail to Detailed information on the handling of user data can be found in our Data Protection Statement.